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Independent predictors of CI-AKI using forward and backward stepwise logistic
regression analyses.
Cumulative Kaplan-Meier Estimates of the Rates of the Mortality During the
Follow-up Period
Independent predictors of mortality at follow up using stepwise PHH method.
Conclusion: Our study failed to show significant differences in AKI incidence between
patients with STEMI undergoing PPCI treated with different hydration strategies, in
particular bicarbonate didn’t result superior to saline infusion.
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Background: The decision of invasive treatment of patients with non-ST-segment
elevation myocardial infarction (NSTEMI) and severe renal dysfunction (SRD) is
ambiguous. The aim of this analysis was to compare clinical presentation and 12-month
outcome of patients with NSTEMI and SRD treated invasively and non-invasively.
Methods: All patients with NSTEMI (N=10503) registered in Polish Registry of Acute
Coronary Syndromes (PL-ACS) from 7.2007 to 11.2009 were included. Glomerular
filtration rate (GFR) was estimated for each patient with the use of MDRD equation.
Follow-up mortality was obtained from the government database.
Results: Patients with severe renal dysfunction (GFR <= 30 mL/min/1.73m2) on
admission comprised only 5.5% of the analyzed population (N=575). Of them 38%
were treated invasively and they were of the lower risk profile. Patients treated
invasively were mostly revascularized by PCI, however 12% of them were referred to
bypass surgery. In-hospital as well as 12-month mortality was lower in patients treated
invasively. However, after multivariate adjustment invasive treatment of patients with
NSTEMI and SRD was no significantly associated with the lower 12-month mortality
(HR=0.84, 95%CI = 0.64-1.12, P=0.24).
Conclusion: Invasive treatment of selected patients with NSTEMI and severe renal
dysfunction seems to be safe and do not lead to higher mortality.
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Background: Complex PCI of multiple vessel disease and chronic total occlusion may
require high dose of contrast media. The risk of contrast induced nephropathy (CIN)
in patients (pts) undergoing such interventions with baseline normal renal function is
unknown as well as the predictive value of Cystatin C (CyC), a marker of renal function
more sensitive than serum creatinine (SCr)
Methods: We evaluated 110 consecutive pts (90 males, age 60 ± 10 yrs) with MDRD
glomerular filtration rate (GFR) > 60 ml/min undergoing complex PCI with contrast
media volume > 400cc. SCr was measured at baseline, 24h, 48h, D6 and between 1
and 6 months after PCI. CyC was measured at baseline, 24h and 48 h post-PCI. Major
adverse events (MACE) including death of any cause, dialysis and TLR were assessed
at 6 months follow-up.
Results: Baseline Scr, MDRD GFR and CyC were 82 ± 14 μmol/l, 87 ± 19 ml/min
and 0.81 ± 0.19 mg/l, respectively. Contrast medium volume was 647±224 cc. CIN
defined as a +25% or +0.5mg/dl increase in Scr at 48h occurred in 11/111 pts (10%)
with persistent CIN at 30 days in only 4 pts (3.6%). No patient underwent dialysis.
MACE rates were similar in CIN and non-CIN pts (18% vs 6%, ns). CIN pts did not
differ from non-CIN pts regarding contrast medium dose, baseline SCr and MDRD
GFR. When compared with non-CIN pts, CIN pts had a greater baseline CyC (0.96±
0.25mg/l vs 0.80 ± 0.17mg/l, p=0.005), a lower weight (64 ±15 vs 78±14 kg, p=0.007),
a lower LVEF (47±19% vs 60±10‰, p=0.0006) and were more frequently smokers
(82% vs 41%, p=0.02). Multivariate analysis showed that baseline CyC ≥ 0.85mg/l
and LVEF ≤ 35% were the only independent predictive factors of CIN. None of the
pts with both baseline CyC < 0.85mg/l and EF > 35% (n=63) had a CIN despite very
high dose of contrast medium (mean 656cc, range 400-1150)
Conclusion: Our data suggest that very high volume of contrast medium can be safely
used if needed in PCI pts with normal baseline renal function providing Cystatin C is
below 0.85mg/l and left ventricular function is not severely depressed.
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Background: In patients undergoing angiography, Contrast-Induced Nephropathy
(CIN) is a major controversial subject which accounts for significant morbidity and
mortality. Though several interventions have been used to prevent CIN, current
evidence does not support the use of prophylactic hemodialysis (HD) to prevent CIN.
Methods: We studied 103 patients with chronic renal impairment (mean serum
creatinine concentration 1.79±0.72 mg/dl), who underwent simultaneous HD during
both diagnostic and intervetional catheterization in catheterization laboratory. Serum
Creatinine (Scr) was measured to evaluate renal function. HD was started just before
administration of contrast media and continued 30min after procedure, and they were
monitored in catheter laboratory during procedure. Blood is driven through the
introducer placed in right atrium at a rate of 300ml/h, and dialysate flow was 500ml/h
without water removal. After extracorporeal circuit, blood was returned back to
saphenous vein. We monitored Scr before catheterization, 24 hours after the procedure
and at the selected time points between 3 to 10 days after the procedure. CIN defined
as an increase in the Scr of 0.5mg/dl or a 25% increase of the Scr at the following day.
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